Company news

Spyre Therapeutics, Inc. news in 2026

Spyre Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Spyre Therapeutics Announces Grants of Inducement Awards

November 6, 2026

Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

November 3, 2026

Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026

October 18, 2026

Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock

October 5, 2026

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

October 5, 2026

Spyre Therapeutics Announces Grants of Inducement Awards

October 2, 2026

Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations

September 8, 2026

Spyre Therapeutics to Participate in Upcoming September Investor Conferences

September 3, 2026

Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072

August 25, 2026

Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa

August 10, 2026

Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 4, 2026

Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients

June 14, 2026

Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA

June 3, 2026

Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 5, 2026

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million

April 15, 2026

Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock

April 13, 2026

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

April 12, 2026

Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients

April 12, 2026

Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026

April 9, 2026

Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026

March 15, 2026

Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

February 19, 2026

Spyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination Approach

February 18, 2026

Spyre Therapeutics Announces Grants of Inducement Awards

February 6, 2026

Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2

January 11, 2026

Decks in 2026